Deputy Director, Research Graduate School

I have a keen interest in identifying targets for the immunotherapy of cancer.

These proteins can also act as biomarkers for survival and early detection markers in urine and blood.

Other References

• www.researchgate.net/profile/Barbara_Guinn/topics
• uk.linkedin.com
• @BarbaraGuinn1
• www.la-press.com/barbara-guinn-eic154

Qualifications

• BSc (Hons) Genetics - University of Aberystwyth
• PhD in Medicine - University of Wales College of Medicine, Wales
• FHEA - University of Bedfordshire
• FRSB

Teaching Expertise

• Undergraduate Biochemistry (L4) and Essential Skills (L4)
• Haematology (L5) and Human Genetics (L6)
• Masters level cancer and therapy, nucleic acid therapies
• Undergraduate and postgraduate lab-based project students

Research Interests

• Identification and characterisation of tumour antigens
• Identification of biomarkers as markers of survival and disease progression
• Analysis of tumour antigen specific T cell populations in cancer patients

Current Research Projects

• Characterisation of tumour antigens in colon cancer
• Detection of urine biomarkers in ovarian cancer
• Identification of tumour antigens in acute lymphocytic leukaemia
• Analysis of cancer-antigens as immunotherapeutic targets

Publications

Last 5 years

• Brooks, S.E., Bonney, S., Lee, C., Publicover, A., Khan, G., Smits, E.L., Sigurdardottir, D., Arno, M., Li, D., Mills, K.I., Pulford, K., Banham, A.H., van Tendeloo, V., Mufti, G.J., Rammensee, H.G., Elliott, T.J., Orchard, K.H. & Guinn, B.A. (2015) Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis. In Press, Public Library of Science One.
• Hofmann, S., Hardwick, N.R., Malinovskis, A., Mead, A., Greiner, J. & Guinn, B.A. (2015) Analogue peptides for the immunotherapy of acute myeloid leukaemia. Cancer Immunology, Immunotherapy. 10.1007/s00262-015-1762-9
• Khan, G., Brooks, S.E., Mills, K.I. & Guinn, B.A. (2015) Infrequent expression of the cancer-testis antigen, PASD1, in ovarian cancer. Biomarkers in Cancer, 7, 31-38.
• Collin, J.F., Wells, J., Czepulkowski, B., Lyne, L., Duriez, P., Banham, A.H., Mufti, G.J. & Guinn, B.A. (2015) A novel zinc finger gene, ZNF465, is inappropriately expressed in presentation acute myeloid leukaemia cells. Genes, Chromosomes & Cancer, 54, 288-302.
• Whelan, M.C., Casey, G., O. Larkin, J., Guinn, B.A., O'Sullivan, G.C., & Tangney, M. (2014) Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. Public Library of Science One, 9, e97602.
• Khan, G., Denniss, F., Mills, K.I., Pulford, K. & Guinn, B.A.  (2014) PASD1: a promising target for the immunotherapy of haematological malignancies. Journal of Genetic Syndromes & Gene Therapy, 4, 186. Invited review for a special issue on "Cancer Genetics".
• Khan, G. & Guinn, B.A. (2013) PASD1 (Xq28). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 20, 630-632.
• Guinn, B.A., Lee, C., Richardson, D. & Orchard, K. (2013) Tumour cells in multiple myeloma patients express carcinoembryonic-antigen-related cell adhesion molecule 1. Blood e-Letters.
• Hardwick, N.R., Buchan, S., Ingram, W., Khan, G., Vittes, G., Rice, J., Pulford, K., Mufti, G.J., Stevenson, F.K. & Guinn, B.A. (2013) An analogue peptide from the cancer testis antigen, PASD1, induces CD8+ T cell-responses against naturally processed peptide. Cancer Immunity, 13, 16-26.
• Stafford, R., Smith, V.A., Husmeier, D., Grima, T. & Guinn, B.A. (2013) Predicting ecological regime shift under climate change: new modelling techniques and potential of molecular-based approaches. Current Zoology, 59, 403-417.
• Khan, G. & Guinn, B.A. (2012) SSX2IP Synovial Sarcoma, X breakpoint 2 interacting protein. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 16, 552-554. 
• Hofmann S, Khan G,Boncheva V, Greiner J, Guinn BA. (2013) Vaccination against myeloid leukaemias using newly defined antigens. In Press, Cancer Immunology Immunotherapy. (Ed. by Rees, R.) Oxford University Press.
• Liberante, F.G., Pellagatti, A., Boncheva, V., Bowen, D.T., Mills, K.I., Boultwood, J. & Guinn, B.A. (2013). High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation. British Journal of Haematology, 162, 282-284.
• Boncheva, V., Bonney, S.A., Brooks, S.E., Tangney, M., O'Sullivan, G., Mirnezami, A. & Guinn, B.A. (2013) New targets for the immunotherapy of colon cancer – does reactive disease hold the answer? Cancer Gene Therapy, 20, 157-168.
• Lam, P., Khan, G., Stripecke, R., Hui, K.M., Kasahara, N., Peng, K.-W. & Guinn, B.A. (2013) The innovative evolution of cancer gene and cellular therapies. Cancer Gene Therapy, 20, 141-149.
• Khan G, Brooks SE, Denniss F, Sigurdardottir D, Guinn BA. (2013) Identification and validation of targets for cancer immunotherapy: from the bench-to-bedside. Gene Therapy (Ed. by Wei, M. & Good, D.). IntechOpen. ISBN980-953-307-743-2.
• Khan G, Guinn BA. (2012)SSX2IP Synovial Sarcoma, X breakpoint 2 interacting protein. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 16,552-554.
• Guinn BA, Lee CH, Richardson D,Orchard K. (2011) Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma. European Journal of Haematology, 87, 554-555.
• Smits E, Lee C, Hardwick N, Brooks SE, van Tendeloo VFI, Orchard K, Guinn BA. (2011) Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 60, 757-769.
• Lee CH, Guinn BA, Brooks SE, Richardson D, Orchard K. (2010) CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials. British Journal of Haematology, 149, 795-797.

Contact details

T: +44 (0)1582 743573
E: barbara.guinn@beds.ac.uk